ProNephro AKI (NGAL) is now FDA-Cleared     READ MORE

Search

Announcements

Subscribe to investor news

Investor News

BioPorto

BioPorto A/S

Grant of Warrants

Mon, 01 Sep 2025 16:15 GMT

BioPorto

BioPorto A/S

Tildeling af Warrants

Mon, 01 Sep 2025 16:15 GMT

BioPorto

BioPorto A/S

ProNephro AKI™ (NGAL), early detection test for Acute Kidney Injury, now commercially available to US Labs through BioPorto’s collaboration with Roche Diagnostics.

Thu, 28 Aug 2025 10:06 GMT

BioPorto

BioPorto A/S

ProNephro AKI™ (NGAL), til tidlig diagnosticering af akut nyreskade, er nu kommercielt tilgængelig på laboratorier i USA gennem BioPortos samarbejde med Roche Diagnostics.

Thu, 28 Aug 2025 10:06 GMT

BioPorto

BioPorto A/S

BioPorto Interim Result for the Second Quarter of 2025 - Continued progress with full execution of strategic objectives and strong NGAL sales growth.

Fri, 15 Aug 2025 05:57 GMT

Follow this link to view all historical announcements.